BIOGEN INC. Litigation Settlement, Expense
BIOGEN INC. (BIIB) reported Litigation Settlement, Expense of $4.70 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LitigationSettlementExpense · last filed 2026-04-29
- BIOGEN INC. litigation settlement, expense for the quarter ending 2026-03-31 was $4.70M, a 56.67% increase year-over-year.
- BIOGEN INC. litigation settlement, expense for the quarter ending 2025-03-31 was $3.00M.
- BIOGEN INC. litigation settlement, expense for the quarter ending 2023-12-31 was $3.90M, a 77.06% decline year-over-year.
- BIOGEN INC. litigation settlement, expense for the quarter ending 2023-09-30 was $0.00.
- BIOGEN INC. litigation settlement, expense for fiscal 2025 was $139.50M, a 430.42% increase from fiscal 2024.
- BIOGEN INC. litigation settlement, expense for fiscal 2024 was $26.30M, a 574.36% increase from fiscal 2023.
- BIOGEN INC. litigation settlement, expense for fiscal 2023 was $3.90M, a 99.57% decline from fiscal 2022.
- BIOGEN INC. litigation settlement, expense for fiscal 2022 was $917.00M.
| Period end | Litigation Settlement, Expense 3 month | Litigation Settlement, Expense 6 month | Litigation Settlement, Expense 9 month | Litigation Settlement, Expense 12 month | Litigation Settlement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-03-31 | $4.70M 10-Q · filed 2026-04-29 | ||||
| 2025-12-31 | $139.50M 10-K · filed 2026-02-06 | ||||
| 2025-03-31 | $3.00M 10-Q · filed 2026-04-29 | ||||
| 2024-12-31 | $26.30M 10-K · filed 2026-02-06 | $0.00 10-K · filed 2025-02-12 | |||
| 2023-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-06 | $3.90M derived: sum of 2 quarters · filed 2026-02-06 | $3.90M derived: sum of 3 quarters · filed 2026-02-06 | $3.90M 10-K · filed 2026-02-06 | $0.00 10-K · filed 2024-02-14 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-07-25 | $0.00 10-Q · filed 2023-07-25 | |||
| 2022-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $17.00M derived: sum of 2 quarters · filed 2025-02-12 | $917.00M derived: sum of 3 quarters · filed 2025-02-12 | $917.00M 10-K · filed 2025-02-12 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-08 | $900.00M derived: sum of 2 quarters · filed 2025-02-12 | $900.00M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $900.00M 10-K · filed 2025-02-12 | $900.00M 10-Q · filed 2023-07-25 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $0.00 derived: sum of 2 quarters · filed 2024-02-14 | $0.00 derived: sum of 3 quarters · filed 2024-02-14 | $0.00 10-K · filed 2024-02-14 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-10-25 | $0.00 derived: sum of 2 quarters · filed 2022-10-25 | $0.00 10-Q · filed 2022-10-25 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-07-20 | $0.00 10-Q · filed 2022-07-20 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-15 | ||||
| 2018-12-31 | $0.00 10-K · filed 2019-02-06 | ||||
| 2017-12-31 | $0.00 10-K · filed 2019-02-06 | ||||
| 2016-12-31 | $454.80M 10-K · filed 2019-02-06 | $454.80M 10-K · filed 2019-02-06 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-01 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-02-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |